Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B

We report a 54-year-old male presenting with a history or recurrent nose bleeds and ecchymoses. The coagulation study showed a prolongedpartial thromboplastin time, a factor VIII of 8% and a high inhibitor titer (193 Bethesda units). A diagnosis of acquired hemophilia A was reached. The patient was...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Conte L,Guillermo, Figueroa M,Gastón, Aravena R,Paola, Gonzáles G,Néstor, Araos H,Daniel, Cuneo V,Marianela
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2011
Materias:	Antibodies monoclonal Factor VIII Hemophilia A Rituximab
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000300012
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872011000300012
record_format	dspace
spelling	oai:scielo:S0034-988720110003000122011-08-25Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito BConte L,GuillermoFigueroa M,GastónAravena R,PaolaGonzáles G,NéstorAraos H,DanielCuneo V,Marianela Antibodies monoclonal Factor VIII Hemophilia A Rituximab We report a 54-year-old male presenting with a history or recurrent nose bleeds and ecchymoses. The coagulation study showed a prolongedpartial thromboplastin time, a factor VIII of 8% and a high inhibitor titer (193 Bethesda units). A diagnosis of acquired hemophilia A was reached. The patient was initially treated with cyclophosphamide for seven months without response. Therefore rituximab in doses of 375 mglm²Iweek for four weeks was started. After starting treatment, the patient had a hematoma in the psoas muscle with a concomitantfactor VIII ofless than 5%, thatwas treated with local measures. Thereafter, aprogressive reduction in inhibitor titers was observed, until its disappearance atfive months of treatment. Factor VIII levéis normalized and the patient has not experienced abnormal bleeding episodes. The patient remains in remission after 67 months offollow up. Rituximab, a chimeric monoclonal antibody against theprotein CD 20 is an effective treatment in acquired hemophilia A.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.139 n.3 20112011-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000300012es10.4067/S0034-98872011000300012
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antibodies monoclonal Factor VIII Hemophilia A Rituximab
spellingShingle	Antibodies monoclonal Factor VIII Hemophilia A Rituximab Conte L,Guillermo Figueroa M,Gastón Aravena R,Paola Gonzáles G,Néstor Araos H,Daniel Cuneo V,Marianela Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
description	We report a 54-year-old male presenting with a history or recurrent nose bleeds and ecchymoses. The coagulation study showed a prolongedpartial thromboplastin time, a factor VIII of 8% and a high inhibitor titer (193 Bethesda units). A diagnosis of acquired hemophilia A was reached. The patient was initially treated with cyclophosphamide for seven months without response. Therefore rituximab in doses of 375 mglm²Iweek for four weeks was started. After starting treatment, the patient had a hematoma in the psoas muscle with a concomitantfactor VIII ofless than 5%, thatwas treated with local measures. Thereafter, aprogressive reduction in inhibitor titers was observed, until its disappearance atfive months of treatment. Factor VIII levéis normalized and the patient has not experienced abnormal bleeding episodes. The patient remains in remission after 67 months offollow up. Rituximab, a chimeric monoclonal antibody against theprotein CD 20 is an effective treatment in acquired hemophilia A.
author	Conte L,Guillermo Figueroa M,Gastón Aravena R,Paola Gonzáles G,Néstor Araos H,Daniel Cuneo V,Marianela
author_facet	Conte L,Guillermo Figueroa M,Gastón Aravena R,Paola Gonzáles G,Néstor Araos H,Daniel Cuneo V,Marianela
author_sort	Conte L,Guillermo
title	Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
title_short	Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
title_full	Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
title_fullStr	Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
title_full_unstemmed	Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
title_sort	hemofilia adquirida tratada con anti cd20, un anticuerpo anti linfocito b
publisher	Sociedad Médica de Santiago
publishDate	2011
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000300012
work_keys_str_mv	AT contelguillermo hemofiliaadquiridatratadaconanticd20unanticuerpoantilinfocitob AT figueroamgaston hemofiliaadquiridatratadaconanticd20unanticuerpoantilinfocitob AT aravenarpaola hemofiliaadquiridatratadaconanticd20unanticuerpoantilinfocitob AT gonzalesgnestor hemofiliaadquiridatratadaconanticd20unanticuerpoantilinfocitob AT araoshdaniel hemofiliaadquiridatratadaconanticd20unanticuerpoantilinfocitob AT cuneovmarianela hemofiliaadquiridatratadaconanticd20unanticuerpoantilinfocitob
_version_	1718436557654851584

Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B

Ejemplares similares